Document is current
Any future updates will be listed below
-
Authors
Kelly, Richard J. https://orcid.org/0000-0002-3318-9482
Holt, Matthew https://orcid.org/0009-0003-0685-1543
Szer, Jeff https://orcid.org/0000-0001-6783-2301
-
Funding
Funding for this research was provided by:
University of Melbourne
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 20 August 2025
First Online: 23 September 2025
Declarations
:
: RK: Alexion, Astra-Zeneca Rare Diseases: Speaker bureau, advisory boards and honoraria; Florio: honoraria; Novartis: research funding (to institute), speaker bureau, advisory boards and honoraria; Omeros: honoraria; Otsuka: honoraria; Roche: advisory boards and honoraria; Sobi: research funding (to institute), speaker bureau, advisory boards and honoraria. MH: Sobi: Research funding and honoraria; Novartis: honoraria; Alexion, Astra-Zeneca Rare Diseases: travel support. JS: Sobi: Speaker bureau, advisory board, honoraria and travel support; Alexion, Astra-Zeneca Rare Diseases: honoraria and speaker bureau; Novartis: advisory board, speaker, honoraria and travel support; Eli Lilly, honoraria; Takeda, honoraria.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable: data used to prepare this manuscript were all available in the published literature and references to data form the reference list.
: All authors participated equally in sourcing the data, writing the manuscript and correcting the manuscript. MH developed the figures.
